在早期和晚期MOGCT中保守治疗后的生殖结果
Francesca M Vasta1, Gennaro Cormio2, Chiara Cassani3
1Department of Obstetrics and Gynecology, IRCCS San Raffaele, Milan, Italy.
Gynecologic oncology
|December 17, 2023
概括
对于恶性卵巢生殖细胞瘤 (MOGCTs),节育性手术和BEP化疗允许获得良好的生殖结果. 大多数在治疗后试图怀孕的幸存者成功怀孕,怀孕的愿望是活产的关键因素.
科学领域:
- 妇科 妇科 妇科 妇科
- 在瘤学瘤学.
- 生殖医学 生殖医学
背景情况:
- 恶性卵巢生殖细胞瘤 (MOGCTs) 主要影响年轻女性.
- 标准治疗包括节制生育的手术和分期,随着可选的辅助化疗 (布洛米辛,埃托波西德,西斯普拉丁 - BEP).
研究的目的:
- 为了评估MOGCT幸存者的生殖结果,他们接受了保守的治疗方法.
- 评估辅助化疗对这些患者生育能力的影响.
主要方法:
- 对164名MOGCT幸存者进行了一份关于妇科症状和生殖结果的问卷.
- 分析了1983年至2019年间诊断的114名患者的数据,包括接受化疗的患者.
主要成果:
- 在114名患者中,38名 (33.3%) 试图怀孕,其中29名 (76.3%) 怀孕,总共有44名怀孕.
- 月经恢复发生在BEP化疗后的中位数为5.6个月内;仅报告了一例过早卵巢衰竭病例.
- 怀孕的愿望是妇女试图怀孕后治疗的活产的唯一预测因素.
结论:
- 由于患者的人口统计学,生育能力的保护是MOGCTs的关键考虑因素.
- 对MOGCTs的辅助化疗似乎不会对生殖功能或生育能力产生负面影响,符合现有证据.
相关概念视频
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...